Press release
Migraine Market Size Projected to Grow Rapidly by 2034: FDA Approvals and Strategic Opportunities | DelveInsight
Migraine Market Insight, Epidemiology And Market Forecast - 2034
DelveInsight's "Migraine Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers an in-depth understanding of the current migraine treatment market, emerging therapeutics, and market trends shaping the future of migraine management across the US, EU4 (Germany, Spain, Italy, and France), the UK, and Japan. According to DelveInsight's migraine report, the total migraine market size in the 7MM was approximately USD 11 billion in 2023 and is projected to increase with a decent CAGR during the forecast period (2024-2034).
Furthermore, the US dominated the migraine market in 2023, accounting for approximately USD 7 billion, which is expected to increase by 2034 as innovative therapeutic approaches gain traction.
Download the Migraine Market Forecast Report to understand which factors are driving the Migraine market @ Migraine Market Trends [https://www.delveinsight.com/sample-request/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The migraine patient population continues to expand, with approximately 120K prevalent cases reported across the 7MM in 2023. The US represents the largest patient share at nearly 40%, followed by Japan at 15%. The UK leads among European nations. Furthermore, gender disparities remain pronounced, with females constituting approximately three times the number of cases compared to males in the US. Epidemiological patterns further reveal that episodic migraine significantly outweighs chronic migraine in prevalence. From a commercial perspective, both forms contribute substantially to the overall disease burden and market opportunity.
Discover evolving trends in the Migraine patient pool forecasts @ Migraine Epidemiological Analysis [https://www.delveinsight.com/sample-request/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Current therapeutic approaches primarily focus on acute/abortive and preventive strategies. The acute migraine treatment market is dominated by triptans, which generate the highest revenue, followed by NSAIDs, analgesics/opioids, and dihydroergotamine formulations. For preventive therapy, options include antiepileptics, antihypertensives, and neurotoxins like BOTOX, which remains the only FDA-approved therapy specifically for chronic migraine treatment. The identification of key biomarkers, particularly serotonin 1F receptor and calcitonin gene-related peptide (CGRP), has revolutionised treatment approaches, with CGRP antagonists like Eli Lilly's EMGALITY (galcanezumab-gnlm) and Teva's AJOVY (fremanezumab-vfrm) securing significant market share.
Recent regulatory milestones have accelerated market growth by introducing several significant approvals that expand treatment options for the diverse patient population. In January 2025, the FDA approved Axsome Therapeutics' AXS-07, marketed as Symbravo, a novel oral medication that is rapidly absorbed and employs multiple mechanisms to treat acute migraines in adults, with or without aura. Additionally, in February 2025, the FDA cleared a migraine device designed for children as young as eight years old. In November 2024, Theranica's Nerivio Registered REN wearable received expanded age indications, making it the first FDA-cleared non-drug therapy for acute migraine treatment in children, as well as the only prescribed preventive migraine treatment for this age group.
In April 2025, the FDA approved CT-132, the first prescription digital therapeutic for the preventive treatment of episodic migraine in adults, to be used alongside existing migraine therapies. Delivered via a 12-week smartphone app, CT-132 significantly reduced monthly migraine days and improved quality of life in clinical trials, offering a novel, accessible non-drug option for migraine prevention.
Discover evolving trends in the Migraine treatment landscape @ Migraine Recent Developments [https://www.delveinsight.com/sample-request/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The competitive landscape features several key pharmaceutical players driving innovation in the migraine therapeutics market, including Lundbeck Seattle BioPharmaceutical, Eli Lilly (NYSE: LLY) and Company, Amgen (NASDAQ: AMGN), Novartis (NYSE: NVS), Teva Pharmaceuticals (NYSE: TEVA), Allergan, Biohaven Pharmaceuticals, Dr. Reddy's Labs (NYSE: RDY), AbbVie (NYSE: ABBV), Impel NeuroPharma (NASDAQ: IMPL), Zosano Pharma (NASDAQ: ZSAN), Axsome Therapeutics (NASDAQ: AXSM), Aeon Biopharma (NYSE: AEON), Ionis Pharmaceuticals (NASDAQ: IONS), and Charleston Laboratories, among others. These companies are actively developing next-generation therapies targeting novel mechanisms of action to address treatment gaps in both episodic and chronic migraine management.
Looking ahead, the migraine drugs market is poised for further transformation through emerging pipeline candidates with novel mechanisms of action and improved efficacy profiles. The continued focus on personalised treatment approaches, enhanced diagnostic tools, and expanding patient awareness is expected to drive sustained market growth, offering new hope for millions of individuals worldwide affected by this debilitating neurological condition.
Table of Contents
1. Key Insights
2. Report Introduction
3. Migraine Market Overview at a Glance
4. Executive Summary of Migraine
5. Disease Background and Overview
6. Migraine Treatment
7. Migraine Epidemiology and Patient Population
8. Migraine Patient Journey
9. Migraine Patient Journey
10. Migraine Marketed Therapies
11. Migraine Emerging Therapies
12. Migraine: 7 Major Market Analysis
13. Migraine Market Outlook
14. KOL Views
15. Migraine Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
Related Reports
Migraine Pipeline Insight [https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Migraine Pipeline Insight provides comprehensive insights about the Migraine pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Migraine companies, including Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, and Pear Therapeutics, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=migraine-market-size-projected-to-grow-rapidly-by-2034-fda-approvals-and-strategic-opportunities-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine Market Size Projected to Grow Rapidly by 2034: FDA Approvals and Strategic Opportunities | DelveInsight here
News-ID: 4214639 • Views: …
More Releases from ABNewswire
New YA Adventure "Milly and the Shawl of Athena" Transports Young Readers into a …
A gripping new teen and adventure novel has hit the shelves. Milly and the Shawl of Athena by J P Allen is a genre-defying novel which combines ancient mythology, gaming culture, and heart-wrenching family drama to produce an addictive adventure.
Set in a decade and inspired by the author's love of history, mythology, fiction, and computer games, this first in the planned series features twelve-year-old Milly Martin, whose ordinary life is…
Hudkins Publishing Music Launches Three Volumes of Background Music for Commerci …
Now they are available for every business.
KINGMAN, AZ - October 30, 2025 - Hudkins Publishing Music proudly announces the release of three new instrumental playlists explicitly designed for commercial use in cafes, offices, spas, restaurants, hotels, and creative studios. The new series-Hudkins Background Music Volumes 1-3-offers businesses royalty-free soundtracks that elevate atmosphere, encourage customer relaxation, and improve employee focus.
Each collection features 30 professionally produced instrumental tracks, available in both WAV…
Book Now the Emerging Gospel Artist "Jacqueline L. Jenkins" debuts new single "A …
BIOGRAPHY
Jacqueline L. Jenkins is an emerging gospel artist celebrated for her heartfelt lyrics and soulful vocals that blend traditional gospel spirit with contemporary rhythms. She first gained recognition with her debut single, "Thank You," which resonated deeply with listeners through its message of gratitude and faith. In 2024, Jacqueline released the Thank You - EP, featuring standout tracks such as "Going Home," a poignant tribute to her late mother, and…
Why More People Are Choosing Mobile Hair and Beauty Services Through DashStylist …
People are seeking a means of making their lives easier in the hectic world we all live in. Mobile beauty and hair services are one of the trends that are on the rise. These services help save time and efforts as the salon experience has been delivered to the home of the customer. Customers do not have to drive to a salon, wait until their turn comes and then drive…
More Releases for Migraine
Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share?
The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market?
The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes.
Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR…
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market.
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive…
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which…
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases.
The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs.
Get Access to TOC /…
